- Home
- YSG vs TNGX Comparison
YSG vs TNGX Comparison
Compare YSG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- TNGX
- Stock Information
- Founded
- YSG 2016
- TNGX 2014
- Country
- YSG China
- TNGX United States
- Employees
- YSG N/A
- TNGX N/A
- Industry
- YSG Package Goods/Cosmetics
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- YSG Consumer Discretionary
- TNGX Health Care
- Exchange
- YSG Nasdaq
- TNGX Nasdaq
- Market Cap
- YSG 362.5M
- TNGX 317.4M
- IPO Year
- YSG 2020
- TNGX N/A
- Fundamental
- Price
- YSG $3.98
- TNGX $1.29
- Analyst Decision
- YSG
- TNGX Strong Buy
- Analyst Count
- YSG 0
- TNGX 7
- Target Price
- YSG N/A
- TNGX $12.33
- AVG Volume (30 Days)
- YSG 162.0K
- TNGX 756.3K
- Earning Date
- YSG 05-21-2025
- TNGX 05-07-2025
- Dividend Yield
- YSG N/A
- TNGX N/A
- EPS Growth
- YSG N/A
- TNGX N/A
- EPS
- YSG N/A
- TNGX N/A
- Revenue
- YSG $464,908,550.00
- TNGX $42,069,000.00
- Revenue This Year
- YSG $16.55
- TNGX N/A
- Revenue Next Year
- YSG $13.17
- TNGX N/A
- P/E Ratio
- YSG N/A
- TNGX N/A
- Revenue Growth
- YSG N/A
- TNGX 15.17
- 52 Week Low
- YSG $2.60
- TNGX $1.11
- 52 Week High
- YSG $6.13
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- YSG 45.88
- TNGX 37.63
- Support Level
- YSG $3.42
- TNGX $1.25
- Resistance Level
- YSG $4.23
- TNGX $1.44
- Average True Range (ATR)
- YSG 0.39
- TNGX 0.15
- MACD
- YSG -0.08
- TNGX 0.03
- Stochastic Oscillator
- YSG 32.00
- TNGX 45.00
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The Group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.